Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · IEX Real-Time Price · USD
26.12
+0.58 (2.27%)
May 3, 2024, 12:01 PM EDT - Market open
Protagonist Therapeutics Revenue
In the year 2023, Protagonist Therapeutics had annual revenue of $60.00M with 125.73% growth. Revenue in the quarter ending December 31, 2023 was $60.00M.
Revenue (ttm)
$60.00M
Revenue Growth
+125.73%
P/S Ratio
25.20
Revenue / Employee
$535,714
Employees
112
Market Cap
1.52B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 60.00M | 33.42M | 125.73% |
| Dec 31, 2022 | 26.58M | -776.00K | -2.84% |
| Dec 31, 2021 | 27.36M | -1.27M | -4.44% |
| Dec 31, 2020 | 28.63M | 28.40M | 12,293.07% |
| Dec 31, 2019 | 231.00K | -30.69M | -99.25% |
| Dec 31, 2018 | 30.93M | 10.86M | 54.14% |
| Dec 31, 2017 | 20.06M | - | - |
| Dec 31, 2016 | 0 | - | - |
| Dec 31, 2015 | 0 | - | - |
| Dec 31, 2014 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| National HealthCare | 1.14B |
| Warby Parker | 669.77M |
| InMode | 492.05M |
| Veracyte | 361.05M |
| Dynavax Technologies | 232.28M |
| LeMaitre Vascular | 193.48M |
| Ardelyx | 124.46M |
PTGX News
- 5 weeks ago - Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data - Accesswire
- 6 weeks ago - Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda - Accesswire
- 2 months ago - Protagonist Therapeutics to Participate in Upcoming Investor Conferences - Accesswire
- 2 months ago - Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - Accesswire
- 2 months ago - New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera - Accesswire
- 2 months ago - Protagonist Therapeutics Reports Granting of Inducement Awards - Accesswire
- 3 months ago - New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study - Accesswire
- 3 months ago - Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset - Accesswire